Article

The Xpc gene markedly affects cell survival in mouse bone marrow.

Department of Microbiology and Walther Oncology Center, Indiana University Simon Cancer Center and Walther Cancer Institute, Indianapolis, 46202, USA.
Mutagenesis (Impact Factor: 3.5). 05/2009; 24(4):309-16. DOI: 10.1093/mutage/gep011
Source: PubMed

ABSTRACT The XPC protein (encoded by the xeroderma pigmentosum Xpc gene) is a key DNA damage recognition factor that is required for global genomic nucleotide excision repair (G-NER). In contrast to transcription-coupled nucleotide excision repair (TC-NER), XPC and G-NER have been reported to contribute only modestly to cell survival after DNA damage. Previous studies were conducted using fibroblasts of human or mouse origin. Since the advent of Xpc-/- mice, no study has focused on the bone marrow of these mice. We used carboplatin to induce DNA damage in Xpc-/- and strain-matched wild-type mice. Using several independent methods, Xpc-/- bone marrow was approximately 10-fold more sensitive to carboplatin than the wild type. Importantly, 12/20 Xpc-/- mice died while 0/20 wild-type mice died. We conclude that G-NER, and XPC specifically, can contribute substantially to cell survival. The data are important in the context of cancer chemotherapy, where Xpc gene status and G-NER may be determinants of response to DNA-damaging agents including carboplatin. Additionally, altered cell cycles and altered DNA damage signalling may contribute to the cell survival end point.

0 Bookmarks
 · 
64 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent laboratory and clinical studies have utilized selenium in the form of pure seleno-L-methionine (SeMet) in combination with DNA-damaging cancer chemotherapy drugs. In mice, the selenium protected bone marrow and other tissues from dose-limiting toxicity. In fact, because of the protection from dose-limiting toxicity, a doubling or even tripling of the maximum tolerated dose (MTD) was enabled. Previously we showed that SeMet protects bone marrow by a DNA repair mechanism that requires the XPC DNA repair protein. XPC is rate-limiting and is required for repair of cisplatin or carboplatin adducts. Herein we used a mouse strain that carries a lambda phage reporter gene in the genome that serves as a mutagenesis target. SeMet protects from carboplatin mutagenesis in mouse bone marrow. Methylseleninic acid (MSA), a metabolite of SeMet, also protected against mutagenesis in mouse bone marrow.
    Anticancer research 02/2010; 30(2):291-3. · 1.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Organic selenium compounds are known to prevent certain cancers although mechanisms may be complex. A widely-held view is that selenium compounds can induce apoptosis in cancer cells, or more precisely, in aberrant cells that are undergoing clonal evolution somewhere along the carcinogenesis process. There are at least 20 different selenium compounds, inorganic as well as organic, that have been used in various published studies. Extrapolation between studies should therefore be undertaken with caution. Similarly, it will be important to ascertain the physiological relevance of the selenium concentrations used in some studies. While cancer prevention by selenium is well-established, recently, organic selenium in the form of pure seleno-L-methionine (SeMet) has been used in combination with cancer chemotherapy drugs. SeMet can induce a DNA repair response in some cell types including bone marrow. Cancer cells generally lack a SeMet-inducible DNA repair response. Thus, SeMet appears to selectively regulate a DNA repair pathway and thereby potentially alter responses to cancer chemotherapy drugs. The specific pathway implicated, nucleotide excision DNA repair (NER) is required for repair of cisplatin or carboplatin DNA damage relevant to chemotherapy. Moreover, some studies have implicated NER as a factor in carcinogenesis processes. Thus, the capacity of SeMet to selectively regulate NER may prove useful in both therapeutic and preventive contexts.
    Molecular and Cellular Pharmacology 01/2009; 1(4):218-221.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: About 15 years ago, several groups including ours had used matched pairs of cell lines carrying wild type or mutant p53 genes to ascertain a role for p53 in cell survival. These were isogenic cell lines differing only by p53 status. The trend at that time was to support p53-mediated apoptosis. Accordingly, p53-wildtype cells were sensitive to DNA damage compared to p53-mutant cells which were thought to evade apoptosis. However, this finding was not universal. In particular, after UV-radiation, p53-mutant cells were more sensitive than their wild type p53 counterparts in several studies. The finding that p53 controlled a major DNA repair pathway, nucleotide excision repair (NER) which repairs UV-damage, provided a mechanism for the observations. We coined the term "the two faces of tumor suppressor p53" to illustrate that p53 can on one hand induce apoptosis leading to cell sensitivity, but p53 can also enhance the rate of DNA repair thereby protecting cells from DNA damage. This concept has gained acceptance and has been expanded to other DNA-damaging agents. New insights into how p53 is "switched" from a protective function to an apoptotic function are reviewed.
    Molecular and Cellular Pharmacology 01/2010; 2(3):117-119.

Full-text (2 Sources)

View
26 Downloads
Available from
Jun 5, 2014